| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CERETAS Aktie jetzt für 0€ handeln | |||||
| 22.09. | CERETAS LIMITED: Date of AGM and Closing Date for Director Nominations | 1 | ASX | ||
| 16.09. | Ceretas Completes Key Ultrasound Development Milestone in CUREator+ Cognitive Decline Program | 2 | smallcaps.com.au | ||
| 16.09. | CERETAS LIMITED: Milestone 3 Completed for CUREator Program | 3 | ASX | ||
| 31.08. | Daily Special: Immutep, Etherstack, Clever Culture Systems, Ceretas, Hawk Resources | 6 | Finance News Network | ||
| 31.08. | CERETAS LIMITED: Ethics Committee Approval Secured for Additional Trial Sites | - | ASX | ||
| 31.08. | CERETAS LIMITED: Appendix 4G | 1 | ASX | ||
| 31.08. | CERETAS LIMITED: Corporate Governance Statement | 1 | ASX | ||
| 31.08. | CERETAS LIMITED: Appendix 4E & Annual Report 30 June 2026 | - | ASX | ||
| 13.08. | CERETAS LIMITED: Investor Presentation | 2 | ASX | ||
| 27.07. | CERETAS LIMITED: Initial Director's Interest Notice x 5 | - | ASX | ||
| 23.07. | Lunch Wrap: Jobs boom clips ASX as Ceretas flies on debut | 3 | Stockhead | ||
| 23.07. | CERETAS LIMITED: Ceretas Lists on ASX | 1 | ASX | ||
| 22.07. | CERETAS LIMITED: Becoming a substantial holder | 1 | ASX | ||
| 22.07. | CERETAS LIMITED: Becoming a substantial holder | 1 | ASX | ||
| 22.07. | CERETAS LIMITED: Becoming a substantial holder | 1 | ASX | ||
| 21.07. | CERETAS LIMITED: Pre-Quotation Disclosure | - | ASX | ||
| 21.07. | CERETAS LIMITED: Securities Trading Policy | - | ASX | ||
| 21.07. | CERETAS LIMITED: Corporate Governance Statement | - | ASX | ||
| 21.07. | CERETAS LIMITED: Employee Securities Incentive Plan | - | ASX | ||
| 21.07. | CERETAS LIMITED: Half-Year Report 31 December 2025 | - | ASX |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BICO GROUP | 2,070 | +2,22 % | BICO Group AB: BICO Completes Integration of Cellenion into SCIENION, Strengthening Precision Biotech Platform | BICO Group AB (publ) today announces the completion of the integration of Cellenion into SCIENION, bringing the businesses, technologies, and teams together under a single organization and brand.
This... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 37,500 | +2,12 % | Fresenius Medical Care Aktie: Wechsel an der Konzernspitze | Fresenius Medical Care bekommt kurzfristig einen neuen Vorstandschef. Shervin J. Korangy übernimmt mit Wirkung zum 12. Oktober 2026 den Vorsitz des Vorstands. Der Aufsichtsrat hat die Personalie am... ► Artikel lesen | |
| FRESENIUS | 42,355 | +1,84 % | JEFFERIES stuft Fresenius SE auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Fresenius vor einem Treffen mit dem Chef Michael Sen auf "Buy" mit einem Kursziel von 55 Euro belassen. Die geschäftliche... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 7,545 | 0,00 % | Morning Market Movers: Veea, NFT Limited, WISeSat.Space, Alignment Healthcare See Big Swings | NEW YORK CITY (dpa-AFX) - At 8:15 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 39,140 | +2,30 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 63,75 | +0,01 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| GENEDX | 67,33 | 0,00 % | GeneDx: Starkes Wachstum trifft auf schwachen Forderungseinzug | ||
| CARL ZEISS MEDITEC | 32,420 | +4,38 % | 200-Tage-Linie hält: Goldman verpasst Zeiss Meditec einen Dämpfer | Goldman Sachs stuft Carl Zeiss Meditec auf "Sell" ab und senkt das Kursziel auf 23 Euro. Zwischenzeitlich verlor das Papier gut sieben Prozent, fing sich dann aber knapp über der 200-Tage-Linie. Die... ► Artikel lesen | |
| STARLING ONCOLOGY INSTITUTE | 6,630 | 0,00 % | The Oncology Institute Rebrands as Starling Oncology | CERRITOS, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI" or "the Company"), one of the largest value-based oncology groups in the United States, announced today that... ► Artikel lesen | |
| HEARTFLOW | 49,730 | -0,02 % | Biotech Stocks At 52-Week Highs - Vaxcyte +31% On Phase 3 Results, InfuSystem, Illumina +7%, Charles River Laboratories +7%, HeartFlow +5% | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on October 5, 2026, driven by key catalysts such as encouraging clinical research data.Vaxcyte Inc. (PCVX)Vaxcyte is... ► Artikel lesen | |
| DRAEGERWERK | 116,60 | +4,67 % | Draegerwerk AG & Co. KGaA: Sechsjähriger FDA-Belastungsfaktor beseitigt; US-Monitoring-Geschäft rückt wieder in den Fokus; KAUFEN | Dräger hat ein sechs Jahre währendes regulatorisches Kapitel im US-Patientenmonitoring endlich abgeschlossen. Nach der FDA-Freigabe (Clearance) von Dräger IACS VG8.1 hat die Behörde den 2020 ausgesprochenen... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 12,235 | -0,12 % | Biotech Stocks At 52-Week Highs - Park Dental Partners +10%, Aveanna Healthcare +24%, Candel Therapeutics +10% on Q2 Reports, Labcorp Holdings, Hemab Therapeutics | LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 12,435 | 0,00 % | Transcript: LifeStance Health Gr Q2 2026 Earnings Conference Call | ||
| BILLIONTOONE | 98,14 | +0,05 % | BillionToOne, Inc.: BillionToOne's Tissue-Free Northstar Response Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds | MENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen | |
| PROGYNY | 27,940 | +0,04 % | Progyny expects 1.2 million new covered lives in 2027 |